Clinical trial
Immunogenicity and Safety of the Sanofi Pasteur DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) Given as a Three-Dose Primary Vaccination at 6, 10, and 14 Weeks of Age and Followed by a Booster Dose at 18-19 Months of Age in Healthy Infants in India.
NCT00259337 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Immunogenicity and Safety of the Sanofi Pasteur DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) Given as a Three-Dose Primary Vaccination at 6, 10, and 14 Weeks of Age and Followed by a Booster Dose at 18-19 Months of Age in Healthy Infants in India.
- Lead sponsor
- Sanofi
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 28, 2006
- Completion date
- December 31, 2008
- Enrollment
- 226 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
diphtheria, haemophilus infections, pertussis, polio, tetanus